Loading
Total declarations
Companies
▲ Purchases (10 ops.)
▼ Sales (4 ops.)
Latest filing published 16 Jul 2026 for InMed Pharmaceuticals Inc., €6,644. Read the official filing
Filing timeline
BuySaleVivo Opportunity, LLC
Insider track record
Disclosed buys
10
Disclosed sells
4
Signal history
Closed purchases
Market purchases
10
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Since each purchase
- -11.8%Entry US$1.52 · Close 14 Oct 2026 US$1.34
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Vivo Opportunity, LLC: trading record in brief
Vivo Opportunity, LLC discloses dealings in 4 companies, chiefly InMed Pharmaceuticals Inc., Soleno Therapeutics Inc and Terns Pharmaceuticals, Inc. The record holds 18 filings, for trades running from 26 January 2022 to 16 July 2026.
Market trades split into 10 purchases (€30.0M) and 4 sales (€80.5M). Sales outweigh purchases by €50.6M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 3 share grants. So far in 2026, the count stands at 6 purchases and no sales.
In size, the median ticket on the buying side is €13k. Scaled by market value, the purchases weigh a median 0.019% of market cap (sample: 6 purchases). Of 10 purchases, 4 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster.
The latest filing, published on 16 July 2026, reports an open-market purchase of €6,644 in InMed Pharmaceuticals Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Vivo Opportunity, LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations16 total
4,882 shares@ US$1.550.100% mcap23.8% of flowCommon SharesSEC:0001213900-26-078891:0
Canonical exit: 12 Oct 2026 (T+90)
493 shares@ US$1.550.010% mcap2.4% of flowCommon SharesSEC:0001213900-26-078891:1
Canonical exit: 12 Oct 2026 (T+90)
13,761 shares@ US$1.550.28% mcap66.9% of flowCommon SharesSEC:0001213900-26-078891:2
Canonical exit: 13 Oct 2026 (T+90)
1,389 shares@ US$1.550.028% mcap6.8% of flowCommon SharesSEC:0001213900-26-078891:3
Canonical exit: 13 Oct 2026 (T+90)
19 shares@ US$1.550.0004% mcap0.1% of flowCommon SharesSEC:0001213900-26-078891:4
Canonical exit: 14 Oct 2026 (T+90)
2 shares@ US$1.550.0000% mcap0.0% of flowCommon SharesSEC:0001213900-26-078891:5
Canonical exit: 14 Oct 2026 (T+90)
400,000 shares@ US$65.8025.1% of flowCommon StockSEC:0001013762-25-004322:0
500,000 shares@ US$48.7322.4% of flowCommon StockSEC:0001213900-24-074051:0
750,000 shares@ US$47.8034.4% of flowCommon StockSEC:0001213900-24-038343:0
136,255 shares@ US$6.997.7% of flowCommon StockSEC:0001213900-24-030020:0
5,215,000 shares@ US$2.5012.8% of flowCommon StockSEC:0001013762-23-001637:0
3,203,093 shares@ US$1.755.4% of flowCommon StockSEC:0001213900-23-080555:0
758,620 shares@ US$7.2545.2% of flowCommon StockSEC:0001213900-22-082664:0
Canonical exit: 23 Mar 2023 (T+90)
600,000 shares@ US$3.6018.8% of flowCommon StockSEC:0001213900-22-054888:0
Canonical exit: 6 Dec 2022 (T+90)
1,123,021 shares@ US$2.9828.3% of flowCommon StockSEC:0001213900-22-048763:0
Canonical exit: 10 Nov 2022 (T+90)
161,712 shares@ US$55.0030.2% of flowCommon StockSEC:0001213900-22-036724:0
▲
Same trade as the filing by Gaurav Aggarwal, counted once · View ↗
800,000 shares@ US$27.0068.8% of flowCommon StockSEC:0001213900-22-004647:0
Canonical exit: 1 May 2022 (T+90)
24,996 shares@ US$13.201.0% of flowCommon StockSEC:0001213900-22-004318:0
18 of 16 declarations
